Your browser doesn't support javascript.
Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays.
Shurrab, Farah M; Al-Sadeq, Duaa W; Amanullah, Fatima Humaira; Al-Absi, Enas S; Qotba, Hamda; Yassine, Hadi M; Abu-Raddad, Laith J; Nasrallah, Gheyath K.
  • Shurrab FM; Biomedical Research Center, Qatar University, Doha, Qatar.
  • Al-Sadeq DW; Biomedical Research Center, Qatar University, Doha, Qatar.
  • Amanullah FH; College of Medicine, Member of QU Health, Qatar University, Doha, Qatar.
  • Al-Absi ES; Biomedical Research Center, Qatar University, Doha, Qatar.
  • Qotba H; Biomedical Research Center, Qatar University, Doha, Qatar.
  • Yassine HM; Department of Clinical Research, Primary Health Care Centers, Doha, Qatar.
  • Abu-Raddad LJ; Biomedical Research Center, Qatar University, Doha, Qatar.
  • Nasrallah GK; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
Intervirology ; 65(4): 224-229, 2022.
Article in English | MEDLINE | ID: covidwho-1673579
ABSTRACT
Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid testing kits. However, some rapid test kits have low specificity and can generate false positives. Hence, we aimed to investigate the potential serological cross-reactivity between SARS-CoV-2 and DENV-IgG antibodies using advanced assays including chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) test. A total of 90 DENV-IgG-ELISA-positive and 90 DENV-IgG-ELISA-negative prepandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA-positive and 91 SARS-CoV-2-IgG-CLIA-negative postpandemic sera were tested for anti-DENV-IgG using the NovaLisa ELISA kit. The DENV-IgG-positive sera resulted in five positives and 85 negatives for SARS-CoV-2-IgG. Similarly, the DENV-IgG-negative sera also resulted in 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG-positive and DENV-IgG-negative sera was found (p value = 1.00). The SARS-CoV-2-IgG-positive sera displayed 43 positives, 47 negatives, and 1 equivocal for DENV-IgG, whereas the SARS-CoV-2-IgG-negative sera resulted in 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG-positive and SARS-CoV-2-IgG-negative sera (p value = 0.58). In conclusion, there is a low risk of serological cross-reactivity between the DENV and SARS-CoV-2-IgG antibodies when using advanced detection assays.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dengue Virus / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Intervirology Year: 2022 Document Type: Article Affiliation country: 000522479

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dengue Virus / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Intervirology Year: 2022 Document Type: Article Affiliation country: 000522479